Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:49 UTC |
---|
Update Date | 2021-09-14 15:15:54 UTC |
---|
HMDB ID | HMDB0014440 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Morphine |
---|
Description | Morphine is the principal alkaloid in opium and the prototype opiate analgesic and narcotic. In 2017, morphine was the 155th most commonly prescribed medication in the United States, with more than four million prescriptions. Morphine is used primarily to treat both acute and chronic severe pain. Its duration of analgesia is about three to seven hours. A large overdose of morphine can cause asphyxia and death by respiratory depression if the person does not receive medical attention immediately. Morphine is naturally produced by several plants (such as the opium poppy) and animals (PMID: 22578954 ). Morphine was first isolated between 1803 and 1805 by Friedrich Sertürner. Sertürner originally named the substance morphium after the Greek god of dreams, Morpheus, as it has a tendency to cause sleep. The primary source of morphine is isolation from poppy straw of the opium poppy. Morphine is also endogenously produced by humans. In the mid 2000s it was found morphine can be synthesized by white blood cells (PMID 22578954 ). CYP2D6, a cytochrome P450 isoenzyme, catalyzes the biosynthesis of morphine from codeine and dopamine from tyramine. The morphine biosynthetic pathway in humans occurs as follows: L-tyrosine -> para-tyramine or L-DOPA -> dopamine -> (S)-norlaudanosoline -> (S)-reticuline -> 1,2-dehydroretinulinium -> (R)-reticuline -> salutaridine -> salutaridinol -> thebaine -> neopinone -> codeinone -> codeine -> morphine. (S)-Norlaudanosoline (also known as tetrahydropapaveroline) which is an important intermediate in the WBC biosynthesis of morphine can also be synthesized from 3,4-dihydroxyphenylacetaldehyde (DOPAL), a metabolite of L-DOPA and dopamine. Morphine has widespread effects in the central nervous system and on smooth muscle (PMID: 4582903 ). The precise mechanism of the analgesic action of morphine is not fully known. However, specific CNS opiate receptors have been identified and likely play a role in the induction of analgesic effects. Morphine first acts on the mu-opioid receptors. The mechanism of respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to increases in carbon dioxide tension and electrical stimulation. It has been shown that morphine binds to and inhibits GABA inhibitory interneurons. These interneurons normally inhibit the descending pain inhibition pathway. So, without the inhibitory signals, pain modulation can proceed downstream. When the dose of morphine is reduced after long-term use, opioid withdrawal symptoms such as drowsiness, vomiting, and constipation may also occur (PMID: 23244430 ). Morphine is only found in easily detectable quantities in individuals that have used or taken this drug. |
---|
Structure | [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1 |
---|
Synonyms | Value | Source |
---|
(-)-Morphine | ChEBI | (5alpha,6alpha)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol | ChEBI | (5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol | ChEBI | (5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol | ChEBI | (7R,7AS,12BS)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol | ChEBI | Morfina | ChEBI | Morphia | ChEBI | Morphin | ChEBI | Morphinum | ChEBI | Morphium | ChEBI | Morfina dosa | Kegg | Substitol | Kegg | (5a,6a)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol | Generator | (5Α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol | Generator | (5a,6a)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol | Generator | (5Α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol | Generator | D-(-)-Morphine | HMDB | Morphina | HMDB | Morphine sulfate | HMDB | Contin, MS | HMDB | Morphine chloride | HMDB | Morphine sulfate (2:1), anhydrous | HMDB | Oramorph SR | HMDB | Sulfate, morphine | HMDB | Chloride, morphine | HMDB | MS Contin | HMDB | Duramorph | HMDB | Morphine sulfate (2:1), pentahydrate | HMDB |
|
---|
Chemical Formula | C17H19NO3 |
---|
Average Molecular Weight | 285.3377 |
---|
Monoisotopic Molecular Weight | 285.136493479 |
---|
IUPAC Name | (1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10,15-tetraene-10,14-diol |
---|
Traditional Name | morph |
---|
CAS Registry Number | 57-27-2 |
---|
SMILES | [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O |
---|
InChI Identifier | InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1 |
---|
InChI Key | BQJCRHHNABKAKU-KBQPJGBKSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic. |
---|
Kingdom | Organic compounds |
---|
Super Class | Alkaloids and derivatives |
---|
Class | Morphinans |
---|
Sub Class | Not Available |
---|
Direct Parent | Morphinans |
---|
Alternative Parents | |
---|
Substituents | - Morphinan
- Phenanthrene
- Tetralin
- Coumaran
- Alkyl aryl ether
- 1-hydroxy-2-unsubstituted benzenoid
- Aralkylamine
- Piperidine
- Benzenoid
- Secondary alcohol
- Tertiary amine
- Tertiary aliphatic amine
- Ether
- Oxacycle
- Azacycle
- Organoheterocyclic compound
- Organopnictogen compound
- Organooxygen compound
- Organonitrogen compound
- Organic oxygen compound
- Alcohol
- Hydrocarbon derivative
- Organic nitrogen compound
- Amine
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 255 °C (sulfate salt) | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 10.2 g/L | Not Available | LogP | 0.8 | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross SectionsAdduct Type | Data Source | CCS Value (Å2) | Reference |
---|
[M+H]+ | CBM | 164.0 | 30932474 |
|
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Morphine,1TMS,isomer #1 | CN1CC[C@]23C4=C5C=CC(O[Si](C)(C)C)=C4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5 | 2473.9 | Semi standard non polar | 33892256 | Morphine,1TMS,isomer #2 | CN1CC[C@]23C4=C5C=CC(O)=C4O[C@H]2[C@@H](O[Si](C)(C)C)C=C[C@H]3[C@H]1C5 | 2450.8 | Semi standard non polar | 33892256 | Morphine,2TMS,isomer #1 | CN1CC[C@]23C4=C5C=CC(O[Si](C)(C)C)=C4O[C@H]2[C@@H](O[Si](C)(C)C)C=C[C@H]3[C@H]1C5 | 2490.4 | Semi standard non polar | 33892256 | Morphine,1TBDMS,isomer #1 | CN1CC[C@]23C4=C5C=CC(O[Si](C)(C)C(C)(C)C)=C4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5 | 2744.1 | Semi standard non polar | 33892256 | Morphine,1TBDMS,isomer #2 | CN1CC[C@]23C4=C5C=CC(O)=C4O[C@H]2[C@@H](O[Si](C)(C)C(C)(C)C)C=C[C@H]3[C@H]1C5 | 2729.0 | Semi standard non polar | 33892256 | Morphine,2TBDMS,isomer #1 | CN1CC[C@]23C4=C5C=CC(O[Si](C)(C)C(C)(C)C)=C4O[C@H]2[C@@H](O[Si](C)(C)C(C)(C)C)C=C[C@H]3[C@H]1C5 | 2974.9 | Semi standard non polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental GC-MS | GC-MS Spectrum - Morphine EI-B (Non-derivatized) | splash10-00li-8970000000-28acaf307ce4bc5aabf1 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Morphine CI-B (Non-derivatized) | splash10-014i-0090000000-b9cf42b077ae0fa5b50d | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Morphine EI-B (Non-derivatized) | splash10-00li-8970000000-28acaf307ce4bc5aabf1 | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Morphine CI-B (Non-derivatized) | splash10-014i-0090000000-b9cf42b077ae0fa5b50d | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Morphine GC-MS (Non-derivatized) - 70eV, Positive | splash10-00vl-1090000000-adcd23ce75ad17f72cc5 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Morphine GC-MS (2 TMS) - 70eV, Positive | splash10-03mi-7209800000-b1a234139ee9e72f3402 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Morphine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Morphine LC-ESI-QTOF , positive-QTOF | splash10-000i-0090000000-98125212ed8e73f219e1 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Morphine LC-ESI-QTOF , positive-QTOF | splash10-000i-0090000000-e9f7be236d827a716c1b | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Morphine LC-ESI-QTOF , positive-QTOF | splash10-000i-0290000000-5066e10cd96a2c376676 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Morphine LC-ESI-QTOF , positive-QTOF | splash10-0kui-0930000000-793deeb91de6d2459cbe | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Morphine LC-ESI-QTOF , positive-QTOF | splash10-100r-0900000000-f775c77035946f746daa | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Morphine LC-ESI-ITFT , positive-QTOF | splash10-0ufr-0390000000-660ff44516f98e346016 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Morphine LC-ESI-ITFT , positive-QTOF | splash10-000i-0090000000-22857c8ef81e65ad6bd3 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Morphine LC-ESI-ITFT , positive-QTOF | splash10-000i-0090000000-c5194c99a9e7f30ea0c8 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Morphine LC-ESI-ITFT , positive-QTOF | splash10-000i-0090000000-1980ff8ab9e654f16fe1 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Morphine LC-ESI-ITFT , positive-QTOF | splash10-000i-0690000000-efa51d970eaf96d3b982 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Morphine LC-ESI-ITFT , positive-QTOF | splash10-0pc9-0920000000-64a693f2f51c03129c94 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Morphine LC-ESI-ITFT , positive-QTOF | splash10-100r-0900000000-49174c3db4b1c1847080 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Morphine LC-ESI-ITFT , positive-QTOF | splash10-000i-0090000000-3cc8784093ef460d3030 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Morphine LC-ESI-ITFT , positive-QTOF | splash10-000i-0090000000-4bc885836f18b77696f3 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Morphine LC-ESI-ITFT , positive-QTOF | splash10-000i-0090000000-4a16648c3e86669f2446 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Morphine LC-ESI-ITFT , positive-QTOF | splash10-000i-0690000000-f41b2f804790e9ad8f1d | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Morphine LC-ESI-ITFT , positive-QTOF | splash10-0pc9-0920000000-69393fc6563baf39d91f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Morphine LC-ESI-ITFT , positive-QTOF | splash10-100r-0900000000-467f39309be5edfa4c01 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Morphine LC-ESI-ITFT , positive-QTOF | splash10-0ufr-0390000000-bd9670761ff2a7dafc55 | 2017-09-14 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Morphine 10V, Positive-QTOF | splash10-000i-0090000000-46d12300d5a1a45af278 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Morphine 20V, Positive-QTOF | splash10-000i-0090000000-9470e4073083d671574a | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Morphine 40V, Positive-QTOF | splash10-0pdj-3290000000-3c229ae6f1433ae20d85 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Morphine 10V, Negative-QTOF | splash10-001i-0090000000-0d38f6180c7ffdd17c4e | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Morphine 20V, Negative-QTOF | splash10-001i-0090000000-e3fd836bcbf266246e22 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Morphine 40V, Negative-QTOF | splash10-02di-0390000000-317675bcd07b96b05935 | 2016-08-03 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum |
|
---|